Delete search term

Header

Main navigation

Health Technology Assessment: Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis

Key data

Project team

Cécile Grobet, Maxim Sharakin, Linda Vinci, Maria Carlander, Flurina Meier, Prof. Dr. Philipp Egli, Prof. Dr. Andreas Gerber-Grote, Prof. Dr. Simon Wieser

Project status

completed, 01/2020 - 10/2021

Institute/Centre

Winterthur Institute of Health Economics (WIG); School of Health Sciences; Institute of Enterprise Law (IUR)

Funding partner

Bundesamt für Gesundheit BAG / Sektion Health Technology Assessment (HTA)

Project budget

165'000 CHF